Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

DGAP-Adhoc: Eckert & Ziegler Reorganizes its Production Sites

eqs_en 
0 0 05.03.20
DGAP-Adhoc: Eckert & Ziegler Reorganizes its Production Sites
 

DGAP-Ad-hoc: Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s): Real Estate
Eckert & Ziegler Reorganizes its Production Sites

05-March-2020 / 20:24 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

- Sale of Belgian special purpose property initiated
- One-off income expected

Berlin, 5 March 2020. Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700, S-DAX) will reorganize its global network of radiopharmaceutical production sites and in this context sell a special property in Seneffe, Belgium. A corresponding agreement was notarised today- and, in addition to the sale of the building, also includes the transfer of the handling license and liability for any dismantling obligations. The transfer is subject to customary market conditions precedent. The necessary conditions include in particular the approval of the Belgian supervisory authority. The transfer and the associated effects on the balance sheet will only become effective once the supervisory authority has issued a positive decision.

If the authority approves the transfer as requested, this would result in a release of the disposal reserves previously held for the Belgian production building. This change in the balance sheet would result in a one-off income of 2.7 Mio. EUR for Eckert & Ziegler.

Your contact:
Eckert & Ziegler AG, Karolin Riehle, Investor Relations
Robert-Rössle-Str. 10, 13125 Berlin, Germany
Tel.: +49 (0) 30 / 94 10 84-138, [email protected], www.ezag.com

Information and Explanation of the Issuer to this News:

With the merger of the Belgian prostate implant specialist IBt in 2008, Eckert & Ziegler BEBIG SA took over a production site where cyclotrons were used to produce precursors for low-level radioactive implants. Since new production sites are planned in Asia and North America as part of a realignment and globalization of the Pharmaceuticals division, Eckert & Ziegler is now divesting from this special property.

05-March-2020 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de
Language: English
Company: Eckert & Ziegler Strahlen- und Medizintechnik AG
Robert-Rössle-Str.10
13125 Berlin
Germany
Phone: +49 30 941084-138
Fax: +49 30 941084-112
E-mail: [email protected]
Internet: www.ezag.de
ISIN: DE0005659700
WKN: 565970
Indices: SDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 991105

 
End of Announcement DGAP News Service

991105  05-March-2020 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=991105&application_name=news&site_id=sharewise

Eckert & Ziegler Strahlen- und Medizintechnik AG Stock

€37.24
0.000%
The Eckert & Ziegler Strahlen- und Medizintechnik AG price is unchanged compared to yesterday.
With 6 Buy predictions and not the single Sell prediction the community is currently very high on Eckert & Ziegler Strahlen- und Medizintechnik AG.
With a target price of 95 € there is potential for a 155.1% increase which would mean more than doubling the current price of 37.24 € for Eckert & Ziegler Strahlen- und Medizintechnik AG.
Show more
Like: 0
Share
eqs_en 
EQS Group is a leading international provider of regulatory technology in the fields of corporate compliance and investor relations. In working with EQS Group, thousands of companies worldwide inspire trust by fulfilling complex national and international disclosure obligations, minimizing risks and communicating transparently with stakeholders.




Legal notice

Comments

Not a member yet? Sign up for free!